Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
SINOVAC BIOTECH LTD (SVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
08/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"SINOVAC Reports Unaudited First Half of 2023 Financial Results"
05/25/2023 SC 13D/A SAIF Partners IV L.P. reports a 15% stake in SINOVAC BIOTECH LTD.
05/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F BEIJING, China, May 1, 2023 /Business Wire/ -- Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2022. The Company also reported its unaudited financial for the second half and audited financial for full year ended December 31, 2022. Second Half and Full Year 2022 Financial Summary"
04/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
03/15/2023 SC 13D/A SAIF Partners IV L.P. reports a 15% stake in SINOVAC BIOTECH LTD.
02/22/2023 8-A12B/A Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]
02/22/2023 6-K Quarterly results
12/29/2022 6-K Quarterly results
12/12/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/04/2022 6-K Quarterly results
06/09/2022 6-K Quarterly results
05/06/2022 6-K Quarterly results
04/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Sinovac Biotech Ltd."
04/29/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/22/2022 8-A12B/A Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]
02/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Third Amendment to Amended and Restated Rights Agreement between Sinovac Biotech Ltd. and Pacific Stock Transfer Company, as Rights Agent",
"Sinovac Amends Shareholder Rights Plan"
12/30/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"SINOVAC Reports Unaudited First Half of 2021 Financial Results"
12/13/2021 6-K Quarterly results
12/10/2021 6-K Quarterly results
12/07/2021 6-K Quarterly results
11/10/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Preliminary Results Show SINOVAC’ s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population BEIJING, China, November 9, 2021 -- SINOVAC Biotech Ltd. , a leading provider of biopharmaceutical products in China, announced new preliminary data on its inactivated COVID-19 vaccine CoronaVac®. The results from statistics analysis under blind status indicated that CoronaVac® is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age. The multi-center, case-driven, randomized, double-blind, and placebo-controlled phase III study is currently being conducted in South Africa, Chile, Malaysia, and the Philippines. As of October 2021, a total of 2,140 participants ranging from 6 months to 17 years o..."
07/20/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine to Support Global Polio Endgame Strategy"
07/20/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"SINOVAC’ s CoronaVac Used on Child Population in China, Good Antibody Levels Observed After Three Months Following Vaccination"
07/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"SINOVAC Enters Into Agreement to Supply CoronaVac ® to COVAX"
06/30/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Sinovac Biotech Ltd."
06/02/2021 6-K Quarterly results
04/22/2021 6-K Quarterly results
04/22/2021 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
04/02/2021 6-K Quarterly results
02/22/2021 8-A12B/A Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]
02/22/2021 6-K Quarterly results
02/08/2021 6-K Quarterly results
12/23/2020 GN 1Globe Capital, the Largest Shareholder of Sinovac Biotech, Reached Agreement with SEC and Calls on All Stakeholders to Support Sinovac's COVID-19 Vaccine Program
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy